Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Are New Variants On The Way?

<< Previous

Bullboard Posts

Next >>

Comment by woundedkneeon Jul 12, 2021 4:05pm

194 Views

Post# 33530898

RE:RE:RE:RE:RE:RE:RE:RE:Are New Variants On The Way?

You two laugh and demean all you want, it just shows how uninformed you both are. You both are entitled to your opinion, which is very weak. And by the way actuarial,.it has not a damn thing to do with Trump. It has to do with evidence coming from renown scientists, which Bill gates is not. Be nice to have a leader of the western world who doesn't have alzheimers. What a sad situation. And Mugsy, you should stick to pumping antibe

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario